Wire · opportunities
FDA approves Camzyos for adolescents with symptomatic obstructive hypertrophic cardiomyopathy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
The FDA approved mavacamten (Camzyos) for adolescents aged 12 to younger than 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), supported by the phase 3 SCOUT-HCM trial demonstrating significant reduction in left ventricular outflow tract obstruction. This is the first cardiac myosin inhibitor approved for this younger patient group, offering a new targeted treatment option.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
You have a new market open with the first targeted drug for adolescent obstructive hypertrophic cardiomyopathy. This approval shifts treatment from symptom management to disease mechanism targeting, creating fresh opportunities in pediatric cardiac care.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics